In contrast, the phospho-AMPK and Akt/mTOR signaling pathways were activated in OR CRC cells, reducing tumor-suppressive autophagy, which protects these cells by increasing the levels of enzymes involved in glycolysis, especially GLUT1, PFKFB3 and PFK1, thereby maintaining resistance to oxaliplatin. The gene discussed is SLC2A1; the disease is colorectal carcinoma.